We are live on ! Find out more
GILD icon

Gilead Sciences

1,263 hedge funds and large institutions have $116B invested in Gilead Sciences in 2014 Q2 according to their latest regulatory filings, with 163 funds opening new positions, 527 increasing their positions, 461 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more first-time investments, than exits

New positions opened: 163 | Existing positions closed: 83

46% more funds holding in top 10

Funds holding in top 10: 112164 (+52)

14% more repeat investments, than reductions

Existing positions increased: 527 | Existing positions reduced: 461

6% more funds holding

Funds holding: 1,1891,263 (+74)

0% less capital invested

Capital invested by funds: $116B → $116B (-$569M)

24% less call options, than puts

Call options by funds: $2B | Put options by funds: $2.62B

Holders
1,263
Holders Change
+74
Holders Change %
+6.22%
% of All Funds
36.28%
Holding in Top 10
164
Holding in Top 10 Change
+52
Holding in Top 10 Change %
+46.43%
% of All Funds
4.71%
New
163
Increased
527
Reduced
461
Closed
83
Calls
$2B
Puts
$2.62B
Net Calls
-$624M
Net Calls Change
+$552M
Name Holding Trade Value Shares
Change
Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$961M -$10.6M -135,653 -1%
UBS AM
27
UBS AM
Illinois
$901M -$28.4M -364,798 -3%
MCM
28
Marsico Capital Management
Colorado
$875M -$44.8M -574,990 -5%
O
29
OppenheimerFunds
New York
$848M +$15.5M +198,698 +2%
Capital International Investors
30
Capital International Investors
California
$824M -$38.5M -494,300 -5%
Deutsche Bank
31
Deutsche Bank
Germany
$780M +$95.1M +1,221,998 +15%
American Century Companies
32
American Century Companies
Missouri
$755M -$102M -1,304,267 -13%
Brown Advisory
33
Brown Advisory
Maryland
$710M -$9.64M -123,795 -1%
Edgewood Management
34
Edgewood Management
Connecticut
$655M -$75M -963,687 -11%
WRF
35
Waddell & Reed Financial
Kansas
$647M -$241M -3,097,407 -28%
Winslow Capital Management
36
Winslow Capital Management
Minnesota
$596M -$49.3M -632,778 -8%
Morgan Stanley
37
Morgan Stanley
New York
$572M +$70.8M +909,540 +15%
Legal & General Group
38
Legal & General Group
United Kingdom
$532M +$789K +10,140 +0.2%
CGT
39
Capital Guardian Trust
California
$524M -$82.2M -1,056,603 -14%
ECU
40
Egerton Capital (UK)
United Kingdom
$510M +$479M +6,148,743 New
OH
41
Orbis Holdings
Bermuda
$510M +$273M +3,501,459 +132%
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$500M +$57.5M +739,332 +14%
PI
43
Putnam Investments
Massachusetts
$491M +$30M +385,093 +7%
MC
44
Montag & Caldwell
Georgia
$474M -$25M -320,615 -5%
GE
45
General Electric
Ohio
$447M +$10.8M +138,160 +3%
William Blair & Company
46
William Blair & Company
Illinois
$441M +$2.5M +32,165 +0.6%
U
47
UBS
Switzerland
$437M +$84.4M +1,084,490 +26%
IIS
48
Ignis Investment Services
United Kingdom
$422M -$197K -2,532 -0.5%
CS
49
Credit Suisse
Switzerland
$419M -$3.03M -38,881 -0.8%
Allianz Asset Management
50
Allianz Asset Management
Germany
$414M -$20.1M -258,041 -5%

GILD Hedge Fund Activity: Q2 2014 in Review

1,263 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2014, worth a combined $116B — down 0.49% from $116B a quarter earlier.

Buyers outnumbered sellers: 163 funds opened new GILD positions and 83 closed out — a net gain of 80 holders — while 527 added to existing stakes and 461 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $1.16B. The largest seller was BNP Paribas Financial Markets, cutting an estimated $3.85B.

  • 1,263 institutional investors held Gilead Sciences (GILD) as of Q2 2014, up from 1,189 in Q1 2014.
  • Funds reported $116B of Gilead Sciences stock for Q2 2014, down 0.49% quarter-over-quarter.
  • 163 funds opened new Gilead Sciences positions in Q2 2014 and 83 closed out, a net change of +80 holders.
  • The largest Gilead Sciences buyer in Q2 2014 was Capital Research Global Investors, an estimated $1.16B added.
  • The largest Gilead Sciences seller in Q2 2014 was BNP Paribas Financial Markets, an estimated $3.85B sold.

Based on aggregated 13F filings for Q2 2014.